// App-Quantinova.ai

2541 : Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors.

Researchers

Presenter

  • Paul Elvin

Principal Investigators

  • Amy Palmer

  • Chris Womack

  • Helen Ambrose

  • Christine Stephens

  • Barry Davies

  • Andrew Foxley

  • Martin Pass

  • Elizabeth A. Harrington

  • Michelle D Garrett

  • Udai Banerji

  • Kenji Tamura

  • S Y Amy Cheung

  • Peter Lawrence

  • Justin Lindemann

  • J. Carl Barrett

  • Matthew Tall

  • Karen E Swales

Medical Centers

  • AstraZeneca, Waltham, MA

  • AstraZeneca Oncology Innovative Medicines, Macclesfield, United KingdomThe Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United KingdomThe Institute of Cancer Research, Sutton, United Kingdom

  • Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan

Locations

  • United States

  • United Kingdom

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • AZD-5363

Outcome

  • Indeterminate

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01226316

Sponsors

  • AstraZeneca.

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved